Efficacy of the Vacucis Candida® Autovaccine

NANot yet recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2027

Conditions
Oral CandidiasisOral Candidiasis RecurrentRadiotherapy; ComplicationsCandida Albicans InfectionMicrobial ColonizationXerostomia
Interventions
DRUG

Vacucis autovaccine

A sample will be taken from all participants in group T following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory. After 1 month from the sample collection, the laboratory will send in a container/dispenser (with the same appearance in both groups) to the T group will be administered the complete autovaccine ((with two applications per day for 7 weeks)

DRUG

Placebo

A sample will be taken from all participants in group P following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory (as in group T). After 1 month from the collection of the sample, the laboratory will send it in a container/dispenser (with the same appearance in both groups). The content in group P will receive a placebo in the same dosage and temporality as group T, it will be the same except for the active ingredient, that is, only thimerosal, methylcellulose, sodium chloride and orange essence.

Trial Locations (1)

15785

Universidad de Santiago de Compostela, Santiago de Compostela

All Listed Sponsors
lead

University of Santiago de Compostela

OTHER

NCT05289375 - Efficacy of the Vacucis Candida® Autovaccine | Biotech Hunter | Biotech Hunter